[1. Raab M S, Podar K, Breitkreutz I et al. Multiple myeloma. Lancet 2009; 374:324 - 339.10.1016/S0140-6736(09)60221-X]Search in Google Scholar
[2. Joan Blade, Carlos Fernandez de Larrea, Laura Rosinol. Extramedullary involvement in multiple myeloma. Haematologica. 2012 Nov; 97(11): 1618-1619.10.3324/haematol.2012.078519348743123125242]Open DOISearch in Google Scholar
[3. Blade J, Fernandez de Larrea C, Rosinol L, Cibeira MT, Jimenez R, Powles R. SoftTissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805-12.10.1200/JCO.2011.34.929021900099]Open DOISearch in Google Scholar
[4. Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM, Potter MN, Ethell ME, Shaw BE, Morgan GJ. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009 Feb;50(2):230-5.10.1080/1042819080265775119197724]Search in Google Scholar
[5. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: longitudinal study on 1,003 consecutive patients. Ann Oncol. 2009;21(2):325-30.10.1093/annonc/mdp32919633044]Search in Google Scholar
[6. Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM, et al. The impact of extramedullary disease at presentation in outcome of myeloma. Leuk Lymphoma. 2009;50(2):230-5.10.1080/10428190802657751]Search in Google Scholar
[7. Blade J, Lust J, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 patients. J Clin Oncol. 1994;12(11):2398-404.10.1200/JCO.1994.12.11.23987964956]Open DOISearch in Google Scholar
[8. Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Heamatol. 1996;93(2):345-51.10.1046/j.1365-2141.1996.5191061.x8639427]Search in Google Scholar
[9. Soutar R, Lucraft H, Jackson G, Reece A, Bird J, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004 Mar;124(6):717-26.10.1111/j.1365-2141.2004.04834.x15009059]Search in Google Scholar
[10. Menke DM1, Horny HP, Griesser H, Tiemann M, Katzmann JA, et al. Primary lymph node plasmacytomas (plasmacytic lymphomas). Am J Clin Pathol. 2001 Jan;115(1):119- 26.10.1309/L2GR-PCFM-G4A3-GHDW11190797]Search in Google Scholar
[11. Masood A, Hudhud KH, Hegazi A, Syed G. Mediastinal plasmacytoma with multiple myeloma presenting as a diagnostic dilemma. Cases J. 2008 Aug 21;1(1):116.10.1186/1757-1626-1-116253329818717993]Search in Google Scholar
[12. Miyazaki T, Kohno S, Sakamoto A, Komori K, Sasagawa I et al. A rare case of extramedullary plasmacytoma in the mediastinum. Intern Med. 1992 Dec;31(12):1363-5.10.2169/internalmedicine.31.13631300172]Search in Google Scholar
[13. Kazama T, Ng CS, Giralt SA. Multiphasic CT and MRI appearances of extramedullary multiple myeloma involving the stomach, pancreas, and bladder. Clin Imaging. 2005 JulAug;29(4):263-5.10.1016/j.clinimag.2004.11.00215967318]Search in Google Scholar
[14. Aguado B, Inigo B, Sastre JL, Oriol A. Extramedullary plasmacytomas in the context of multiple myeloma. Adv Ther. 2011 Nov;28 Suppl 7:7-13.10.1007/s12325-011-0073-622105528]Open DOISearch in Google Scholar
[15. Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016 Feb 25;127(8):971-6. 10.1182/blood-2015-07-63538326679866]Search in Google Scholar
[16. Rosiñol L, Cibeira MT, Blade´ J, et al: Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 89:832-836, 2004.]Search in Google Scholar
[17. Avigdor A, Raanani P, Levi I, et al: Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma 42:683-687, 2001. 10.3109/1042819010909933011697498]Search in Google Scholar
[18. Myers B, Grimley C, Crouch D, et al: Lack of response to thalidomide in plasmacytomas. Br J Haematol 115:234, 2001.10.1046/j.1365-2141.2001.115_1cr-6.x]Search in Google Scholar
[19. Nakazato T, Suzuki K, Mihara A, et al. Refractory plasmablastic type myeloma with multiple extra medullary plasmacytomas and massive myelomatous effusion: remarkable response with a combination of thalidomide and dexamethasone. Intern Med. 2009;48:1827-1832.10.2169/internalmedicine.48.214219834276]Open DOISearch in Google Scholar
[20. Gonzalez-Porras JR, Gonzalez M, Garcia-Sanz R, et al. Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas. Br J Haematol. 2002;119:883-884.10.1046/j.1365-2141.2002.03870_8.x12437681]Search in Google Scholar